DDInter504 DDInter1925
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Desipramine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Desipramine {u} (Compound) upregulates {v} (Gene) ACAT2
ACAT2 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Desipramine {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Desipramine {u} (Compound) causes {v} (Side Effect) Eosinophilia
Eosinophilia {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Desipramine {u} (Compound) resembles {v} (Compound) Oxcarbazepine
Oxcarbazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Desipramine {u} (Compound) resembles {v} (Compound) Amitriptyline
Amitriptyline {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Desipramine {u} (Compound) resembles {v} (Compound) Protriptyline
Protriptyline {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Desipramine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Desipramine {u} (Compound) binds {v} (Gene) ORM1
ORM1 {u} (Gene) interacts with {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Vemurafenib
Desipramine {u} (Compound) upregulates {v} (Gene) ACAT2
ACAT2 {u} (Gene) regulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Desipramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Desipramine (Compound) upregulates ACAT2 (Gene) and ACAT2 (Gene) is downregulated by Vemurafenib (Compound)
Desipramine (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Vemurafenib (Compound)
Desipramine (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Vemurafenib (Compound)
Desipramine (Compound) resembles Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Desipramine (Compound) resembles Amitriptyline (Compound) and Amitriptyline may lead to a major life threatening interaction when taken with Vemurafenib
Desipramine (Compound) resembles Protriptyline (Compound) and Protriptyline may lead to a major life threatening interaction when taken with Vemurafenib
Desipramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Desipramine (Compound) binds ORM1 (Gene) and ORM1 (Gene) interacts with ALB (Gene) and ALB (Gene) is bound by Vemurafenib (Compound)
Desipramine (Compound) upregulates ACAT2 (Gene) and ACAT2 (Gene) regulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Vemurafenib (Compound)